BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/22
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 05/05/22
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/22
After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?The Motley Fool • 04/19/22
Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?Zacks Investment Research • 04/14/22
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood DisorderBenzinga • 04/08/22
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack RatesBenzinga • 02/24/22
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)GlobeNewsWire • 02/24/22
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/23/22
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/23/22
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 02/23/22